Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
8.88
-0.34 (-3.69%)
At close: Mar 28, 2025, 4:00 PM
9.45
+0.57 (6.42%)
After-hours: Mar 28, 2025, 6:06 PM EDT
Myriad Genetics Revenue
In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth. Myriad Genetics had revenue of $210.60M in the quarter ending December 31, 2024, with 7.12% growth.
Revenue (ttm)
$837.60M
Revenue Growth
+11.21%
P/S Ratio
0.96
Revenue / Employee
$310,222
Employees
2,700
Market Cap
810.82M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
Jun 30, 2020 | Pro | Pro | Pro |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MYGN News
- 4 weeks ago - Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO - Benzinga
- 4 weeks ago - Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth - GlobeNewsWire
- 4 weeks ago - Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - GlobeNewsWire
- 5 weeks ago - Myriad Genetics Included in Forbes America's Best Employers 2025 List - GlobeNewsWire
- 7 weeks ago - Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - GlobeNewsWire
- 7 weeks ago - Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewsWire
- 7 weeks ago - Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - GlobeNewsWire